Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F19%3A73596357" target="_blank" >RIV/61989592:15110/19:73596357 - isvavai.cz</a>
Result on the web
<a href="https://www.nejm.org/doi/10.1056/NEJMoa1816714" target="_blank" >https://www.nejm.org/doi/10.1056/NEJMoa1816714</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1816714" target="_blank" >10.1056/NEJMoa1816714</a>

Result language
angličtina
Original language name
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Original language description
Background The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear. Methods In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)